✦ LIBER ✦

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

✍ Scribed by Burmester, Gerd R; Blanco, Ricardo; Charles-Schoeman, Christina; Wollenhaupt, Jürgen; Zerbini, Cristiano; Benda, Birgitta; Gruben, David; Wallenstein, Gene; Krishnaswami, Sriram; Zwillich, Samuel H; Koncz, Tamas; Soma, Koshika; Bradley, John; Mebus, Charles

Book ID: 120162769
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 344 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(12)61424-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of tofacitinib (CP-690,55

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

✍ Yoshiya Tanaka; Makoto Suzuki; Hiroyuki Nakamura; Shigeyuki Toyoizumi; Samuel H. 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 301 KB 👁 2 views

A phase IIb dose-ranging study of the or

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

✍ Joel M. Kremer; Stanley Cohen; Bethanie E. Wilkinson; Carol A. Connell; Jonathan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views

Rituximab inhibits structural joint dama

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

✍ Keystone, E. (author);Emery, P. (author);Peterfy, C. G. (author);Tak, P. P. (aut 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 395 KB

Rituximab inhibits structural joint dama

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

✍ Keystone, E. (author);Emery, P. (author);Peterfy, C. G. (author);Tak, P. P. (aut 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 395 KB

Rituximab inhibits structural joint dama

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

✍ Keystone, E. (author);Emery, P. (author);Peterfy, C. G. (author);Tak, P. P. (aut 📂 Article 📅 2008 🏛 BMJ Publishing Group 🌐 English ⚖ 395 KB